Acurx Pharmaceuticals, Inc. (ACXP)

1.6600 +0.0250 (+1.53%) At close: 04:00PM EDT

Acurx Pharmaceuticals, Inc.

259 Liberty Avenue
Staten Island, NY 10305
United States
917 533 1469
https://www.acurxpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 4

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Robert J. DeLuccia	Co-Founder & Executive Chairman	701.54k	N/A	1946
Mr. David P. Luci CPA, Esq., J.D.	Co-Founder, President, CEO & Director	668.98k	N/A	1967
Mr. Robert G. Shawah CPA, CPA	Co-Founder & CFO	470.29k	N/A	1967

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Corporate Governance

Acurx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.